The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label window of opportunity trial to evaluate the activity of durvalumab and tremelimumab with platinum-based chemotherapy (gemcitabine and cisplatin) in intrahepatic cholangiocarcinoma.
 
Olumide B. Gbolahan
Stock and Other Ownership Interests - Pfizer
Consulting or Advisory Role - Exelixis; Incyte; Merck Sharp & Dohme; QED Therapeutics
Speakers' Bureau - OncLive/MJH Life Sciences
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Eisai (Inst); Pfizer (Inst); Zymeworks (Inst)
 
Mehmet Akce
Consulting or Advisory Role - AstraZeneca; Curio Science; Eisai; Eisai; Eisai; Eisai; Exelixis; Genentech; GlaxoSmithKline; Ipsen; Isofol Medical; QED Therapeutics
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Eisai (Inst); IMPAC Medical Systems (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Polaris (Inst); RedHill Biopharma (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst); Xencor (Inst)
 
Darryl Alan Outlaw
Honoraria - OncLive/MJH Life Sciences
 
Grant Richard Williams
Honoraria - Cardinal Health
 
Sushanth Reddy
No Relationships to Disclose
 
Jason Denbo
No Relationships to Disclose
 
Richard D. Kim
Consulting or Advisory Role - Bayer; Exelixis; Lilly; Pfizer; QED Therapeutics; Roche/Genentech; SERVIER; Taiho Oncology
Speakers' Bureau - Eisai; Exelixis; Incyte
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst)
 
Bassel F. El-Rayes
Honoraria - Charles River Associates
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb Foundation; Exelixis; Genentech; QED Therapeutics; Seagen; Stemline Therapeutics; Taiho Oncology
Speakers' Bureau - Intellisphere
Research Funding - Adaptimmune (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); ICON Clinical Research (Inst); IQVIA (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Xencor (Inst); Zymeworks (Inst)
Other Relationship - Erytech Pharma; Exelixis; SC Liver Research Consortium
 
J. Bart Rose
No Relationships to Disclose